Key facts
- It has raised $8.4M; the latest was Early Stage VC in Nov 2024.
- Notable investors include IBK Changgong, Atinum Investment, Heungkuk Securities, KDB NextRound, Stonebridge Ventures (Seoul).
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for De Novo Biotherapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for De Novo Biotherapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About De Novo Biotherapeutics
Developer of an mRNA-encoded anti-cancer treatment technology designed for relapsed or refractory lymphoma diseases. The company designs mRNA to produce bispecific antibodies that attract natural killer (NK) cells, enabling the healthcare sector to discover new drug candidates.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2021
- Employees
- 23
- Website
- denovobio.co.kr/
- Ownership
- Privately Held (backing)
De Novo Biotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in De Novo Biotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on De Novo Biotherapeutics in its N-PORT filings yet. We sweep new filings monthly.